13 June 2018

20:00-22:00  Welcome cocktail and conference registrations

14 June 2018

09:00-09:30  Opening keynotes

09:00-09:10  Opening Speech: Chip Davis, President and Chief Executive Officer - AAM
09:10-09:30  Keynote speech: Mihály Varga, Minister of National Economy, Hungary (inv)

09:30-11:00  1. Markets

Sustainability of the off-patent markets
Moderator: Warwick Smith, Director General - BGMA

Panel
- FDA representative (inv)
- Simon Goeller, Partner - McKinsey
- Knut Slatten, Vice President - Senior Analyst Corporate Finance Group - Moody’s France
- Jean-Guy Goulet, Chief Operating Officer - Pharmascience Inc.
- Jeff Watson, President and Chief Operating Officer - Apotex Inc.
- Pierluigi Antonelli, Head of Western Europe - Sandoz
- Jacek Glinka, President - European Region - Mylan
- Marc-Alexander Mahl, Executive Vice President, Business Unit Generic Drugs - Fresenius Kabi

11:00-11:30  Coffee break

11:30-12:50  2. External factors

New challenges impacting the availability of medicines
Moderator: Adrian van den Hoven, Director General - Medicines for Europe

Panel
- Adele Paterson, CEO and Head of Corporate Partnerships - International Health Partners
- Deborah M. Autor, Head of Strategic Global Quality & Regulatory Policy - Mylan (inv)
- Carissa F. Etienne, Director - PAHO (inv)
- Christian Pawlu, Global Head of Strategy - Sandoz (inv)
- JP speaker (tbi)
3. How to survive
How to manage selective transparency, commoditisation, shortages
Moderator: Frank Bouisset, Head Specialty Growth Franchises West Europe - Sandoz / Chairman of the Hospital Channel WG - Medicines for Europe
Panel:
- Monika Dereque-Pois, Director General - GIRP
- Gergely Németh, Project Manager - National Institute of Health Insurance Fund Management (NEAK)
- Brendan Cuddy, Head Manufacturing and Quality Compliance Service - EMA
- Randall Stanicky, Analyst - RBC Wealth Management
- Canadian speaker (tbi)
- Martin Favié, Chairman - Bogin

4. International cooperation
The impact of international agreements on access to medicines
Moderator: David Gaugh, Senior Vice President for Sciences and Regulatory Affairs - AAM
Panel:
- Mariângela Simão, Assistant DG for Drug Access, Vaccines and Pharmaceuticals - WHO (inv)
- Sandra Kweder, FDA Liaison to EMA (inv)
- Nick Cappuccino - Dr Reddy’s (tbi)

5. Dealing with Data
How to keep up in providing data, recognise its value and make the best use of it
Moderator: (tbc)
Panel:
- Alison Cave, Principal Scientific Administrator - European Medicines Agency
- Lesley Curtis, Professor in Medicine - Duke University, USA (inv)
- John Peter Mary Wubbe, Secretary General - DHE / EPPOSI II / EuDiPPA / ICPEU
- Frederik van Remoortel, Lawyer - Crowell & Moring

6. Fighting the Fakes
The fight against counterfeit medicines
Moderator: Dilip G Shah, Secretary General - IPA
Panel:
- Ana-Eva Ampélas, Head of Unit - European Commission
- Ulrike Kreysa, Senior Vice-President Healthcare - GS1 Global Office
- Desmond Brothers, CEO - Sun Pharma South Africa (inv)
- Craig Stobie, Director - Global Sector Management - Domino
- Andreas Walter, Director General - EMVO

12:50-14:20 Lunch
14:20-15:40
15:40-16:10 Coffee break
16:10-17:30
19:00-23:00 Conference dinner
15 June 2018

09:00-09:30  Opening keynotes

09:00-09:10  Opening address: Marc-Alexander Mahl, President - Medicines for Europe
09:10-09:30  Keynote speech: (tbc)

09:30-11:00  7. Value added medicines
Models to bring better medicines to patients
Moderator: Umberto Comberiati, Chairman Value Added Medicines Sector Group
Panel
- Klara Marton - Egis
- Mariano Votta, Director - Active Citizenship Network (inv)
- Aurelio Arias, Senior Consultant, European Thought Leadership - IQVIA (tbi)
- Kenneth V. Phelps, President and CEO - Camargo Pharmaceutical Services

11:00-11:30  Coffee break

11:30-13:00  8. Biosimilar medicines
Defining a future where trust and regulatory efficiency translate to patient access
Moderator: Michael Soldan, Senior Vice President Head of Biosimilars - Fresenius Kabi (inv)
Panel
- Emer Cooke, Head of Regulation of Medicines and other Health Technologies - WHO (inv)
- Penny Shakespeare, First Assistant Secretary, Technology Assessment and Access Division - Department of Health Australia (inv)
- Zoltán Kaló, Professor of Health Economics and Head of the Institute of Economics - Eötvös Loránd University (ELTE); Founder and CEO - Syreon Research
- Klaus Falk, Vice President - Samsung Bioepis (inv)
- Klaus Martin, President - Apobiologix (inv)
- Markus Sieger, CEO - Polpharma Group

13:00-14:00  Lunch
9. Future strategies

Increasing patient access to specialty medicines
Moderator: Hugo Carradinha, CEO - Pharma Star Brazil (inv)

Panel
- Erin Federman, Head of Biologics (Europe) - Mylan
- Christiane Hanke-Harloff, Director, Biotechnology Business Unit - Gedeon Richter (inv)
- Robert Andrew Johnstone, Patient Advocate - International Foundation for Integrated Care (IFIC), European Forum for Good Clinical Practice (EFGCP) & Health Quality Improvement Partnership (HQIP)
- Jamie Wilkinson, Director of Professional Affairs - PGEU
- James Burt, Executive Vice President, Europe & MENA - Accord Healthcare (inv)
- Rick Lozano, VP Biosimilars & Integrated Business Development - AmerisourceBergen (inv)

15:30 Closing of the conference: Adrian van den Hoven, Director General - Medicines for Europe